CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
Pioglitazone +1 moredrug
Likely dose
Pioglitazone 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00782795
NCT00782795Phase 2Completed
CompareCT.gov

Phase II Study of Chronic Pancreatitis and the Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality

University of Michigan·interventional·Posted Oct 31, 2008·Updated Jan 11, 2018

In Brief

A Phase 2 clinical trial evaluating Pioglitazone and Placebo for Chronic Pancreatitis and 2 related conditions. Completed, enrolled 64 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if study drug (Pioglitazone) treatment will improve pre-diabetes (insulin resistance) or ealy diabetes and improve clinical symptoms (pain) or laboratory evidence of chronic pancreatitis. The goal of the investigators is to gather information from this study to help gain understanding of a potential therapy for chronic pancreatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Pancreatitis, Insulin Resistance, Normal or Mildly Abnormal Stool Fat Levels
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA), Takeda Pharmaceuticals North America, Inc.

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 31, 2008
Enrollment StartNov 1, 2008
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 17.7 years ago

Interventions

Pioglitazonedrug

Participants randomized to pioglitazone receive 30 mg taken once daily for 48 weeks.

Placebodrug